Clinical Trials Browser

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Ureteral Diseases, Ureteral Neoplasms, Urethral Neoplasms

NCT01611662 2019-07-29

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

Phase 2 Terminated

32 enrolled 6 charts

Genitourinary

Urinary Bladder Neoplasms

NCT01191892 2019-05-16

Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

Phase 2 Completed

82 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT02560038 2018-11-28

Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer

Phase 2 Terminated

3 enrolled 9 charts

Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT01089088 2018-10-26

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Phase 2 Completed

63 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00310011 2018-08-10

Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium

Phase 2 Completed

71 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT00089128 2018-07-12

Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Phase 2 Terminated

16 enrolled 4 charts

Genitourinary

Urinary Bladder Neoplasms

Clinical Trials

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

ADAPT-BLADDER

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

GAIN-BCG

TASUC-Neo

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

TRIFECTA

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy

Intravesical Gem/Doce in Patients With NMIBC

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

BCIRT-01

GEMDOCE

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

GETUGV04

OHAI-NMIBC-01

No Acronym

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

NeoSTOP-IT

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

BLAST

NAUTICAL

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

GAIN INST

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

POLO

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer

BIC

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

VINGEM

Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium

Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer